These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 15707858

  • 1. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
    Kruse M, Rosenkranz B, Dobson C, Ayre G, Horowitz A.
    Pulm Pharmacol Ther; 2005; 18(3):229-34. PubMed ID: 15707858
    [Abstract] [Full Text] [Related]

  • 2. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B, Rouzier R, Kruse M, Dobson C, Ayre G, Horowitz A, Fitoussi S.
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [Abstract] [Full Text] [Related]

  • 3. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W, Levine B, Andriano K, Lavecchia C, Yegen U.
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [Abstract] [Full Text] [Related]

  • 4. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhász G.
    Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J, Huchon G, Leclerc V, Vicaut E, Lefrançois G.
    Respiration; 2005 Jul; 72 Suppl 1():6-12. PubMed ID: 15915007
    [Abstract] [Full Text] [Related]

  • 6. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D, Vicaut E, Lefrançois G, Formoterol HFA group.
    Respiration; 2005 Jul; 72 Suppl 1():20-7. PubMed ID: 15915009
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients.
    Molimard M, Guenolé E, Duvauchelle T, Vicaut E, Lefrançois G.
    Respiration; 2005 Jul; 72 Suppl 1():28-34. PubMed ID: 15915010
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.
    Corren J, Korenblat PE, Miller CJ, O'Brien CD, Mezzanotte WS.
    Clin Ther; 2007 May; 29(5):823-843. PubMed ID: 17697902
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/ formoterol dosing.
    Kerwin EM, Oppenheimer JJ, LaForce C, Parasuraman B, Miller CJ, O'Dowd L, Goldman M.
    Ann Allergy Asthma Immunol; 2009 Jul; 103(1):62-72. PubMed ID: 19663129
    [Abstract] [Full Text] [Related]

  • 16. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients.
    Lötvall J, Ankerst J.
    Respir Med; 2008 Mar; 102(3):449-56. PubMed ID: 18023335
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial.
    Pleskow W, LaForce CF, Yegen U, Matos D, Della Cioppa G.
    J Asthma; 2003 Mar; 40(5):505-14. PubMed ID: 14529100
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial.
    Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF.
    Lancet Respir Med; 2013 Mar; 1(1):23-31. PubMed ID: 24321801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.